Výsledky vyhledávání - "Auvro R. Mridha"

Prevascularized Retrievable Hybrid Implant to Enhance Function of Subcutaneous Encapsulated Islets

Autor: Paul D. Dalton, Vijayaganapathy Vaithilingam, Bernard E. Tuch, Luke Carroll, Auvro R. Mridha, Michael B. Morris, Tim R. Dargaville

Publikováno v: Tissue Engineering, 28(5-6), 212-224. Mary Ann Liebert Inc.

Replacement of pancreatic beta-cells is one of the most promising treatment options for treatment of type 1 diabetes (T1D), even though, toxic immunosuppressive drugs are required. In this study, we aim to deliver allogeneic beta-cell therapies witho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f383f8564d12f33390448926412d2e81
https://cris.maastrichtuniversity.nl/en/publications/8e188737-ba81-43a7-9b15-afecf834182c

Zobrazit plný text záznamu

Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice

Autor: Narcissus Teoh, Isabelle Leclercq, Vanessa Barn, W. Geoffrey Haigh, Geoffrey C. Farrell, Laurence Poekes, George N. Ioannou, Hans Wang, Fahrettin Haczeyni, Matthew M. Yeh, Auvro R. Mridha

Publikováno v: Obesity. 25:155-165

Objective Nonalcoholic steatohepatitis (NASH) is the outcome of interactions between overnutrition, energy metabolism, and adipose function. Obeticholic acid (OCA) improves steatosis in patients but for unknown reasons does not resolve NASH pathology

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4496a4da3ebed54d8552df7e80a835e6
https://doi.org/10.1002/oby.21701

Zobrazit plný text záznamu

Encapsulation and Transplantation of Pancreatic Progenitor Cells

Autor: Bernard E. Tuch, Luke Carroll, Auvro R. Mridha

Publikováno v: Methods in Molecular Biology ISBN: 9781493996308

Type 1 diabetes, characterized by autoimmune destruction of pancreatic beta cells, affects 41 million people worldwide. Beta cell replacement therapies have immense potential as a treatment option because pancreatic progenitors derived from human plu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::365f2053d03ff17858d78ab953eaef71
https://doi.org/10.1007/978-1-4939-9631-5_8

Zobrazit plný text záznamu

Exercise improves adipose function and inflammation and ameliorates fatty liver disease in obese diabetic mice

Autor: Mark A. Febbraio, Vanessa Barn, Matthew M. Yeh, Kim S. Bell-Anderson, Narci C. Teoh, Christopher J. Nolan, Auvro R. Mridha, Fahrettin Haczeyni, Emma Estevez, Geoffrey C. Farrell

Publikováno v: Obesity. 23:1845-1855

Objective Adipose inflammation and dysfunction underlie metabolic obesity. Exercise improves glycemic control and metabolic indices, but effects on adipose function and inflammation are less clear. Accordingly, it was hypothesized that exercise impro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::134800ef2cff01901660c1640d0e2845
https://doi.org/10.1002/oby.21170

Zobrazit plný text záznamu

The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice

Autor: Yun-Jung Choi, Narcissus Teoh, Vanessa Barn, Hans Wang, George N. Ioannou, Auvro R. Mridha, W. Geoffrey Haigh, Charles A. McWherter, Fahrettin Haczeyni, Matthew M. Yeh, Geoffrey C. Farrell

Publikováno v: Hepatology Communications

Lipotoxicity associated with insulin resistance is central to nonalcoholic steatohepatitis (NASH) pathogenesis. To date, only weight loss fully reverses NASH pathology, but mixed peroxisome proliferator-activated receptor-alpha/delta (PPAR-α/δ) ago

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a70cd63260acc60fbe7009d820ae126
https://pubmed.ncbi.nlm.nih.gov/29404484

Zobrazit plný text záznamu

6.24 Bioengineering Approaches to Islet Transplantation for Management of Diabetes

Autor: Auvro R. Mridha, B.E. Tuch, Tim R. Dargaville

Human islet transplantation, as currently carried out by portal vein infusion in the liver, can provide good glycaemic control in diabetic patients and can significantly reduce the need to inject exogenous insulin. Perhaps the main challenge in islet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b13dd7451fdf14d2356803b9f93f9035
https://doi.org/10.1016/b978-0-12-803581-8.09316-4

Zobrazit plný text záznamu

TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival

Autor: W. Geoffrey Haigh, Hussam Ajamieh, Vanessa Barn, George N. Ioannou, Fahrettin Haczeyni, Jeffrey M. Hamdorf, Matthew M. Yeh, Leon A. Adams, Narci C. Teoh, Geoffrey C. Farrell, Auvro R. Mridha

Publikováno v: Clinical science (London, England : 1979). 131(16)

Background and aims : TLR9 deletion protects against steatohepatitis due to choline–amino acid depletion and high-fat diet. We measured TLR9 in human non-alcoholic steatohepatitis (NASH) livers, and tested whether TLR9 mediates inflammatory recruit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4079b4a2e5ca7fccd30087f858270a4d
https://pubmed.ncbi.nlm.nih.gov/28687713

Zobrazit plný text záznamu

Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice

Autor: Fahrettin, Haczeyni, Laurence, Poekes, Hans, Wang, Auvro R, Mridha, Vanessa, Barn, W, Geoffrey Haigh, George N, Ioannou, Matthew M, Yeh, Isabelle A, Leclercq, Narcissus C, Teoh, Geoffrey C, Farrell

Publikováno v: Obesity (Silver Spring, Md.). 25(1)

Nonalcoholic steatohepatitis (NASH) is the outcome of interactions between overnutrition, energy metabolism, and adipose function. Obeticholic acid (OCA) improves steatosis in patients but for unknown reasons does not resolve NASH pathology. This stu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::41879d48bda99f74f02e48a442120a0c
https://pubmed.ncbi.nlm.nih.gov/27804232

Zobrazit plný text záznamu

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

Autor: Narci C. Teoh, George N. Ioannou, Avril A. B. Robertson, Fahrettin Haczeyni, Ariel E. Feldstein, Geoffrey C. Farrell, Kate Schroder, Auvro R. Mridha, Alexander Wree, Christopher E. Savard, Mark E. Cooper, Matthew M. Yeh, Casey D. Johnson, Seth L. Masters, Derrick M. Van Rooyen

Publikováno v: Journal of hepatology. 66(5)

Background & Aims NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in Non-alcoholic fatty liver disease (NAFLD). We used the first small molecule NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory rec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8c151fa053d72fcba6b74e595089ba0
https://pubmed.ncbi.nlm.nih.gov/28223701

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání